Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Study Summary

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Conditions

Ovarian Neoplasm Fallopian Tube Neoplasms Peritoneal Neoplasms

Interventions / Drugs

Nab-paclitaxel 80 mg/m^2 Relacorilant 150 mg once daily (QD)Nab-paclitaxel 100 mg/m^2

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment381 participants

Primary Completion—

Lead SponsorCorcept Therapeutics

Data Retrieved2026-04-11 04:10:22.666589+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.